Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|Hormone Receptor Positive Breast Carcinoma
Interventions: DRUG: SM-88
Sponsor: Georgetown University
Collaborators: Tyme, Inc